James T Wu

Title: Innovations in Prostate Cancer Treatment by James T Wu

Introduction

James T Wu is an accomplished inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of medical technology, particularly in the area of prostate cancer treatment. His innovative approach focuses on predicting patient responses to hormonal treatment, which can greatly enhance treatment efficacy.

Latest Patents

James T Wu holds a patent for a method that predicts prostate cancer patients' resistance to hormonal treatment by measuring serum concentrations of chromogranin A. This invention relates to a method for early prediction of a prostate cancer patient's response to hormonal treatment. The method involves assaying a body fluid, such as plasma or serum, from a prostate cancer patient for elevated levels of chromogranin A (CgA). Elevated levels of CgA may indicate neuroendocrine differentiation of cells within the prostate tumor, suggesting a need to alter the patient's treatment. Periodic assays for CgA are conducted for patients undergoing hormonal treatment, with results correlated to determine if CgA levels are high or increasing. This method may also be used alongside assays for total prostate specific antigen (tPSA).

Career Highlights

James T Wu is associated with the Arup Institute, where he continues to work on innovative solutions in medical technology. His dedication to improving patient outcomes through research and development is evident in his work.

Collaborations

James collaborates with Mark E Astill, contributing to advancements in their field. Their partnership exemplifies the importance of teamwork in driving innovation.

Conclusion

James T Wu's contributions to prostate cancer treatment through his patented method highlight the potential for innovation in medical technology. His work not only aids in predicting treatment responses but also paves the way for more personalized patient care.